News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Melanoma Drugs May Steal Market From Roche (RHHBY)


5/29/2012 7:25:44 AM

Two experimental skin cancer drugs from GlaxoSmithKline - each designed to block different pathways used by tumour cells - look set to steal a march on Roche's pioneering melanoma treatment Zelboraf, according to Citigroup. The brokerage, which raised its price target on GSK stock on Monday, forecast combined risk-adjusted annual sales for dabrafenib and trametinib of 1.5 billion pounds ($2.35 billion)by 2020, some three times consensus expectations. Dabrafenib, designed to work in patients with a mutation of a gene known as BRAF, and trametinib, which interferes with a protein known as MEK, have been shown in small-scale tests to curb melanoma with few side effects.

Read at Reuters


comments powered by Disqus
Reuters
   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES